Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning

INTRODUCTION: Obesity is a chronic, relapsing disease associated with substantial cardiometabolic morbidity and reduced quality of life. Although pharmacotherapy has advanced rapidly, current treatment options remain limited by tolerability concerns, access barriers, discontinuation, and reluctance toward injectable agents. Orforglipron, a once-daily oral glucagon-like peptide-1 receptor agonist, represents a potentially important step in expanding effective anti-obesity therapy. AREAS COVERED: This review evaluates the emerging role of orforglipron in obesity pharmacotherapy, with emphasis on its mechanistic basis, clinical pharmacology, efficacy, safety, and likely place in therapy. Particular attention is given to its therapeutic rationale as an oral incretin-based agent, evidence supporting clinically meaningful weight reduction, common adverse effects and prescribing considerations, and its potential positioning relative to established oral anti-obesity drugs and injectable incretin therapies. The review also considers treatment sequencing and the practical implications of integrating oral GLP-1 therapy into routine obesity care. EXPERT OPINION: Orforglipron may benefit patients requiring effective weight-management pharmacotherapy who prefer oral treatment. However, its role should be interpreted cautiously: comparative efficacy may not exceed leading injectable incretin therapies, and long-term durability, persistence, affordability, and real-world safety remain uncertain. Its value will depend on route preference, tolerability, access, and individualized treatment goals.